Martinez R, Marcos M L, Figueras A, Vaquero J
Clin Neuropharmacol. 1984;7(4):338-42. doi: 10.1097/00002826-198412000-00011.
Cytoplasmic estrogen receptor (ER) and progesterone receptor (PR) proteins were measured by a dextran-coated charcoal absorption technique in 19 intracranial tumors (10 meningiomas, two acoustic neurinomas, two glioblastomas, one primary tumor of neuroectodermal origin, one hemangioblastoma, one metastasis of carcinoma, one chordoma, and one pituitary adenoma). Positive PR values (greater than or equal to 10 fmol/mg of protein) were found in nine meningiomas (90% of these tumors), in the chordoma, in one glioblastoma, and in the hemangioblastoma, whereas positive ER values were recorded only in the pituitary adenoma and in one glioblastoma. Evidence of PR in meningiomas might explain their predominance in women. A possible pharmacological therapy, based on these findings, is discussed.
采用葡聚糖包被活性炭吸附技术，对19例颅内肿瘤（10例脑膜瘤、2例听神经瘤、2例胶质母细胞瘤、1例神经外胚层起源的原发性肿瘤、1例血管母细胞瘤、1例癌转移瘤、1例脊索瘤和1例垂体腺瘤）中的细胞质雌激素受体（ER）和孕激素受体（PR）蛋白进行了检测。在9例脑膜瘤（占这些肿瘤的90%）、脊索瘤、1例胶质母细胞瘤和血管母细胞瘤中发现PR值为阳性（大于或等于10 fmol/mg蛋白），而仅在垂体腺瘤和1例胶质母细胞瘤中记录到ER值为阳性。脑膜瘤中PR的存在可能解释了它们在女性中占优势的原因。基于这些发现，讨论了一种可能的药物治疗方法。
